pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·29m ago·1 min read
save

Lilly’s 2026 dealmaking spreads the wealth among biotech venture investors

At least 50 different venture investors have benefited from Eli Lilly’s dealmaking this year, sending early investment dollars back into the startup ecosystem. On Monday, Lilly announced its 13th acquisition of the year, up to ...

Sep 1, 2026·read at Endpoints ↗

Dave Ricks, Lilly CEO (Spencer Platt/Getty Images) September 1, 2026 11:01 AM EDT DealsPharma Lil­ly’s deal­mak­ing spreads the wealth among a broad set of biotech ven­ture in­vestors Kyle LaHucik Biotech Correspondent At least 50 dif­fer­ent ven­ture in­vestors have ben­e­fit­ed from Eli Lil­ly’s deal­mak­ing this year, send­ing ear­ly in­vest­ment dol­lars back in­to the start­up ecosys­tem. On Mon­day … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
91 words · retrieved 21m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 49m agoGSK to launch Phase 3 test of mRNA flu vaccine with newer formulationEndpoints
  • 49m agoRoche taps Simcere for trispecific T cell engager pact with $75M upfrontEndpoints
  • 1h agoAlumis' TYK2 drug fails in lupus trial; CEO sees 'clear path forward'Endpoints
  • 2h agoK Health is eyeing an IPO by 2029Endpoints
  • 3h agoNovartis' Rhapsido safer than rivals, Phase 3 multiple sclerosis data suggestEndpoints